DEKKERS MARIJN E 4
4 · Ginkgo Bioworks Holdings, Inc. · Filed May 14, 2024
Insider Transaction Report
Form 4
DEKKERS MARIJN E
Director
Transactions
- Sale
Class A Common Stock
2024-05-14$0.93/sh−1,727,056$1,606,162→ 281,217 total
Holdings
- 5,780,364(indirect: By Novalis LifeSciences Investments I, L.P.)
Class A Common Stock
Footnotes (3)
- [F1]Includes 281,217 earn-out shares that will vest in substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $15.00, $17.50 and $20.00.
- [F2]The reporting person is the manager of the general partner of Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"), and as such, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences.
- [F3]Includes 464,481 earn-out shares that will vest in substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $15.00, $17.50 and $20.00.